We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Five years after treatment, results showed a freedom ...
The Institutional Review Board Has Approved the Increase in Number of Patients from Sixty (60) to Ninety (90). The Company to Expand the Study into Additional Trial Sites in Europe Philadelphia, ...
Medicus Pharma Ltd. announced promising interim results from its SKNJCT-003 Phase 2 clinical study aimed at the non-invasive treatment of basal cell carcinoma (BCC) using the investigational product D ...
The Company Is on Track to Complete the Interim Data Analysis Before the End of Q1 2025 and to Submit the Findings to the U.S. Food and Drug Administration (FDA) The Company also announced that it is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results